Photonics in Healthcare I
On demand | Presented Live 6 March 2021
Please sign in to view this content.This event is available to paid Photonics West attendees plus Digital Marketplace and Industry Only registrants.
This industry session will look at how photonics-based methods are helping to meet the increasing worldwide demand for rapid, accurate, personalised and cost-effective healthcare interventions – including imaging, diagnostics and therapy. Biophotonics is also instrumental to the analysis of processes at the molecular level, giving a greater understanding of the origin of diseases, and hence allowing prevention and new treatments. Attend this session to learn from industry speakers and see how they are using different photonics technologies to address healthcare needs.
Tom Harvey, Healthcare Photonics Lead, CPI Centre for Healthcare Photonics (United Kingdom)
Muhammad Al-Qaisi, BD Biosciences (United States)
The Next Evolution in Flow Cytometry Instrumentation
Flow Cytometry is an analytical technique that utilizes optical measurements to identify properties of individual cells and particles within large populations. The high-throughput technique measures optical scattering and fluorescence by interrogating a rapidly flowing stream containing suspended objects. The technology has advanced dramatically over the last few decades and became an essential tool of studying cell biology in clinical, research, and translational applications. The photonics industry is expected to play an essential role in the next evolution of the technology to meet the demand of performing higher-parameter measurements, cell imaging, automation, and simplified setup and analysis procedures.
Muhammad Al-Qaisi, PhD, is the Senior Director of Systems and Hardware Engineering at BD Biosciences. He received his PhD in Biomedical Engineering from the University of Minnesota, Twin Cities in 2010. He has more than a decade of technical and leadership experience in the medical device industry. With particular passion to innovate and translate innovations to the hands of users, Muhammad has been part of the launch of several photonics products in the field of lifescience, ophthalmology, and gastrointestinal imaging.
Maaike de Jong , Scinvivo B.V., (The Netherlands)
Optical Coherence Tomography catheter to improve bladder cancer diagnostics
Scinvivo is a medtech startup fully focused on improving the quality of life of bladder cancer patients by improving the current bladder cancer diagnostics and treatment. To achieve this, we are developing an optical coherence tomography (OCT) imaging catheter, which allows the urologist to look up to 3 mm inside the tissue of the bladder wall. The catheter fits in the working channel of a cystoscope, and if the urologist sees something suspicious on the cystoscopy image s/he can insert the catheter and get a cross-sectional image at the point of interest (real time). Reading the guidelines, we've found that Bladder Cancer diagnostics boils down to getting insight into the bladder wall structure to determine the type of tissue and the stage of the tumor growth. With the diagnostic tools currently available this is impossible. Within the current bladder cancer carepath we’ve identified two main “unmet needs” for which our forward-looking OCT-catheter provides the solution:
- differentiating between non-invasive and muscle-invasive bladder cancer as early as possible in the diagnostic phase, and
- the follow-up monitoring of BC patients to reduce the number of unnecessary surgeries caused by false positives.
Maaike de Jong started to work on the development of the Scinvivo catheter in December 2015. She worked fulltime on this project as a part of her PDEng degree Design and Technology of Instrumentation. Maaike has a background in Biomedical Engineering and obtained her Bachelor degree at Eindhoven University of Technology, and her Master degree at Delft University of Technology. She obtained her professional doctorate in engineering (PDEng) at Eindhoven university of Technology. At the beginning of 2017, Maaike spend a five month internship in Boston at Massachusetts General Hospital to specialize in Optical Coherence Tomography and its endoscopic applications. Since September 2017, she works fulltime for Scinvivo.
Seppo Orsila, Modulight (Finland)
Lasers hold promise in oncology for both curative and palliative purposes
Several promising, growing cancer therapies are phototherapies, where lasers play central role. Examples of such phototherapies where Modulight has invested over many years are photoimmunotherapy (PIT) and photodynamic therapy (PDT). In these therapies, non-thermal lasers are used to activate photosensitive drug precisely in the tumor, causing very few side effects thanks to improved spatio-temporal control of treatment compared to mainstream systemic cancer treatments. However, the field is highly regulated and requires multi-disciplinary, collaborative environment for successful clinical implementation. Laser therapies offer clear set of advantages in both curative and palliative cancer treatments, and some examples will be shown in this presentation. The utilization of clinical laser therapies is growing and about to realize their vast potential in standard cancer care.
Mr. Seppo Orsila earned his Ms. Tech. at Tampere University of Technology and MBA from Helsinki School of Economics (2004). He co-founded Modulight in 2000. In 2006 Mr. Orsila pursued a corporate career at Nokia Corp. where he served in number of different finance, sales & strategy roles most recently as CFO of accessories business unit. In 2014 he returned to operational leadership of Modulight.